Methods: In 4 study centers in the Netherlands, 1,811 patients were 1:1 randomly assigned to treatment with one of both stents. Patients with any clinical syndrome, any lesion type, and any number of lesions or vessels to be treated were included. Study monitoring and clinical event adjudication were performed by two independent Dutch contract research organizations (Diagram, Zwolle, and Cardialysis, Rotterdam, respectively).
Results: DUTCH PEERS examines an all-comer patient population that included 59% of patients with acute coronary syndromes (20% of all patients presented with an acute STEMI) and 66% of patients with complex target lesions. We will compare for both stent groups the 2-year incidence of TVF (primary endpoint) and various secondary endpoints, including individual components of the primary endpoint, the incidence of stent thrombosis, and other composite endpoints, such as target lesion failure, major adverse cardiac events, and the patient-oriented composite endpoint. In addition, we will report the outcome of patients with longitudinal stent deformation after discontinuation of dual anti-platelet therapy.
Conclusions: Clinical outcome of the DUTCH PEERS trial at 2-year follow-up will be presented.
|Journal||Journal of the American College of Cardiology|
|Issue number||11, suppl.|
|Publication status||Published - 2014|
|Event||26th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT) 2014 - Washington, United States|
Duration: 12 Sep 2014 → 12 Sep 2014
Conference number: 26